Personalized medicine in lipid-modifying therapy

Brian Tomlinson, Chen Hsiu Lin, Paul Chan, Christopher W.K. Lam

研究成果: 雜誌貢獻回顧型文獻同行評審

1 引文 斯高帕斯(Scopus)


The choice of lipid-modifying treatment is largely based on the absolute level of cardiovascular risk and baseline lipid profile. Statins are the first-line treatment for most patients requiring reduction of low-density-lipoprotein cholesterol (LDL-C) and ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors can be added to reach LDL-C targets. Statins have some adverse effects that are somewhat predictable based on phenotypic and genetic factors. Fibrates or omega-3 fatty acids can be added if triglyceride levels remain elevated. The RNA-Targeted therapeutics in development offer the possibility of selective liver targeting for specific lipoproteins such as lipoprotein(a) and long-Term reduction of LDL-C with infrequent administration of a small-interfering RNA may help to overcome the problem of adherence to therapy.

頁(從 - 到)185-203
期刊Personalized Medicine
出版狀態已發佈 - 3月 2021

ASJC Scopus subject areas

  • 分子醫學
  • 藥理


深入研究「Personalized medicine in lipid-modifying therapy」主題。共同形成了獨特的指紋。